GT Biopharma (GTBP) Net Margin (2010 - 2015)

GT Biopharma (GTBP) posted quarterly Net Margin of 134300.0% for Q2 2015, up 145.82% quarter-over-quarter from 293085.71% in Q1 2015.

GT Biopharma (GTBP) Net Margin (2010 - 2015) Analysis & Trends

GT Biopharma (GTBP) has reported Net Margin for 5 consecutive years, with 134300.0% the latest figure, recorded in Q2 2015.

In Q2 2015, Net Margin changed N/A year-over-year to 134300.0%; the TTM figure through Mar 2016 stood at 68695.0% (down 8720500.0% YoY), while the FY2015 annual figure was 79485.19%, up 446124.0% from the prior year.
Net Margin grew to 134300.0% in Q2 2015 per GTBP's latest filing, from 293085.71% in the prior quarter.
Across five years, Net Margin topped out at 134300.0% in Q2 2015 and bottomed at 293085.71% in Q1 2015.
Historically, Net Margin has averaged 52155.19% across 4 years, with a median of 9615.0% in 2011.
Annual changes were most pronounced in 2012 — Net Margin slumped 17460000 bps — and 2013, when it soared 6204773 bps.
GT Biopharma's Net Margin stood at 37933.33% in 2011, then soared by 102 bps to 595.93% in 2012, then declined by 8 bps to 547.73% in 2013, then soared by 24420 bps to 134300.0% in 2015.
Business Quant data shows GTBP's Net Margin at 134300.0% in Q2 2015, 293085.71% in Q1 2015, and 547.73% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	GT Biopharma	8.38 Mn	8.38 Mn	-	-

Download Data